Clinical Trials
2 trialsNCT04034355 2022-01-26
POLAR-A
Egetis Therapeutics
Phase 3 Terminated
NCT00267007 2014-06-04
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated